Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

203.34
+0.24000.12%
Post-market: 203.00-0.3400-0.17%19:45 EDT
Volume:1.48M
Turnover:301.21M
Market Cap:10.45B
PE:32.22
High:205.81
Open:201.84
Low:201.12
Close:203.10
52wk High:217.12
52wk Low:149.09
Shares:51.40M
Float Shares:51.40M
Volume Ratio:0.77
T/O Rate:2.87%
Dividend:0.35
Dividend Rate:0.17%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.28
PE(LYR):5.75

Loading ...

Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 02

Quantum Computing is Having a Moment. What to Know About the Hottest Sector After AI.

Dow Jones
·
Oct 02

Regeneron Pharmaceuticals, Inc. : Jefferies Raises Target Price to $930 from $870

THOMSON REUTERS
·
Oct 02

More Upside Awaits for Gilead Sciences Stock. Stay Invested.

Dow Jones
·
Oct 02

Vortex Energy Expands Saskatchewan Portfolio with Meadows Project Acquisition

TIPRANKS
·
Oct 02

Vertex adds AI-focused independent director to board

TIPRANKS
·
Oct 02

Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase

TIPRANKS
·
Oct 02

Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
Oct 02

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
Oct 02

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
Oct 02

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
Oct 02

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01